The sale of Silicon Valley Bank’s UK operation to HSBC swiftly solved a massive problem for hundreds of European drug developers, and some of their venture backers, that had cash deposited with the lender. What the loss of a company that provided huge support to the life science sector means for the longer term is harder to know.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,